Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Kudo, Masatoshi; Finn, Richard S.; Morimoto, Manabu et al.
Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)LIVER CANCER. Bd. 10. H. 5. 2021 S. 451-460
Harter, P.; Sehouli, J.; Vergote, I et al.
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerNEW ENGLAND JOURNAL OF MEDICINE. Bd. 385. H. 23. 2021 S. 2123-2131
Hippert, Felicitas; Desing, Lena; Diez, Sonja et al.
Rare Tumors in Children and Adolescents - the STEP Working Group & apos;s Evolution to a Prospective RegistryKLINISCHE PADIATRIE. Bd. 234. H. 03. 2021 S. 146-153
Heilig, C. E.; Horak, P.; Kreutzfeldt, S. et al.
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialESMO OPEN. Bd. 6. H. 6. 2021
Wockel, Achim; Brucker, Cosima; Decker, Thomas et al.
Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA studyCANCER RESEARCH. Bd. 81. H. 4. 2021
Rautenberg, Christina; Stoelzel, Friedrich; Roellig, Christoph et al.
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaBLOOD CANCER JOURNAL. Bd. 11. H. 10. 2021
Boulos, Joelle C.; Saeed, Mohamed E. M.; Chatterjee, Manik et al.
Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma CellsPHARMACEUTICALS. Bd. 14. H. 11. 2021
Kim, Richard D.; Harris, William P.; Sung, Max W. et al.
Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Wiegel, Thomas; Albers, Peter; Bartkowiak, Detlef et al.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial) (Sep, 10.1007/s00432-020-03327-2, 2020)JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 147. H. 1. 2021 S. 243-244
Schmidt, Janine-Alison; Hornhardt, Sabine; Erdmann, Friederike et al.
Risk Factors for Childhood Leukemia: Radiation and BeyondFRONTIERS IN PUBLIC HEALTH. Bd. 9. 2021